NasdaqGS:DXCMMedical Equipment
Assessing DexCom (DXCM) Valuation After Barclays Downgrade On Rising CGM Competition
DexCom (DXCM) is back in focus after Barclays downgraded the stock to Underweight, citing intensifying competition in its core insulin-intensive markets projected for 2026 and 2027, and raising questions about valuation.
See our latest analysis for DexCom.
At a share price of US$74.0, DexCom has seen a 27.10% 90 day share price return and a 10.35% 30 day share price return. However, its 1 year total shareholder return shows a 15.54% decline, signaling fading longer term momentum even as short...